📰 Roche’s US subsidiary, Genentech, has ended its collaboration with AC Immune SA after disappointing study results. It has returned the global rights to two drugs, Crenezumab and Semorinemab, back to AC Immune. The drugs failed to show consistently positive results in recent trials. AC Immune remains focused on progressing its other therapies and is well financed into 2026.
📢 Roche Dumps AC Immune After Failed Trials
Introduction:
Genentech, Roche’s US subsidiary, has decided to end its partnership with AC Immune SA after disappointing results from recent clinical trials. Roche has returned the global rights to AC Immune’s Crenezumab and Semorinemab, two monoclonal antibodies targeting Alzheimer’s disease.
Main points:
- The decision to end the partnership was made after both Semorinemab and Crenezumab failed to consistently show positive results in recent trials.
- AC Immune will now focus on progressing its three active immunotherapies from its precision medicine pipeline.
- AC Immune’s pipeline includes sixteen therapeutic and diagnostic programs, such as ACI-24.060, a potential treatment for Alzheimer’s disease, ACI-7104.056, a treatment for Parkinson’s disease, and ACI-35.030, an investigational therapy for pathological phosphorylated Tau.
- The company has recently received milestone payments and secured financing, allowing it to advance multiple high-value development programs.
Conclusion:
Roche’s decision to end its partnership with AC Immune comes after disappointing results from clinical trials of Semorinemab and Crenezumab. AC Immune will now focus on advancing its precision medicine pipeline, which includes promising treatments for Alzheimer’s disease and Parkinson’s disease.
